Form 8-K - Current report:
SEC Accession No. 0001213900-24-095175
Filing Date
2024-11-07
Accepted
2024-11-07 07:42:21
Documents
16
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220162-8k_jasper.htm   iXBRL 8-K 31110
2 PRESS RELEASE, DATED NOVEMBER 7, 2024 ea0220162ex99-1_jasper.htm EX-99.1 65997
7 GRAPHIC ex99-1_001.jpg GRAPHIC 6939
  Complete submission text file 0001213900-24-095175.txt   338732

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE jspr-20241107.xsd EX-101.SCH 3930
4 XBRL DEFINITION FILE jspr-20241107_def.xml EX-101.DEF 26836
5 XBRL LABEL FILE jspr-20241107_lab.xml EX-101.LAB 37099
6 XBRL PRESENTATION FILE jspr-20241107_pre.xml EX-101.PRE 25460
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0220162-8k_jasper_htm.xml XML 6115
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 241433230
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)